Genital Herpes: Recent Problems and Their Solutions | CMAC

Genital Herpes: Recent Problems and Their Solutions

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):4-18

​ Akovbyan V.A., Masyukova S.A., Vladimirova E.V., Zudin A.B., Pokrovskaya S.B.
genital herpes epidemiology treatment prophylaxis
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):4-18

Abstract

Genital herpes (GH) is widely distributed sexually transmitted disease that is caused by herpes simplex virus type 1 nd 2. This article presents the questions of epidemiology and pathogenesis of this infection. Clinical features and major criteria for diagnosis of GH are described in detail. Special attention is paid to the questions of specific antiviral therapy of GH, such as treatment of primary GH, episodic antiviral therapy, prophylactic use of antiviral agents. Perspectives of therapy and prophylaxis of GH, including specific antivirals as well as vaccines and immunomodulatory agents are also discussed.

  • 1. Бутов Ю.С., Малиновская В.В., Полеско К.В. Герпети-ческая инфекция: патогенетическое обоснование те-рапии. Материалы конференции, посвященной 60-ле-тию кафедры кожвенболезней МГСМУ. Москва;1999. с. 87-8.
  • 2. Benedetti J., Corey L., Ashley R. Recurrence rates in ge-nital herpes after symptomatic first-episode infection.Ann Intern Med 1994;121:847-54.
  • 3. Fleming D.T., McQuillan G.M., Johnson R.E., et al.Herpes simplex virustype 2 in the United States. 1976 to199
  • 4. N Engl J Med 1997;337:1105-11. 4. Johnson R.E., Nahmias A.J., Magder L.S., et al. A seroepi-demiologic survey of the prevalence ofherpes simplexvirustype 2 infection in the United Slates. N Engl J Med1989;321:7-12.
  • 5. Leung D.T., Sacks S.L. Current recommendation for thetreatment of Genital Herpes. Drugs, 2000;60:1329-52.
  • 6. Павлюк А.С. Методы лабораторной диагностики за-болеваний, вызванных вирусом простого герпеса.ЗППП 1994;3:3-7.
  • 7. Халдин А.А., Самгин М.А., Малиновская В.В., Суско-ва В.С. Патогенетическое обоснование современногоподхода к терапии простого герпеса (ПГ). Актуальныепроблемы дерматологии и венерологии: Сб. науч.работ. Москва; 2000. с. 21.
  • 8. Губанова Е.И., Масюкова С.А., Яцуха М.В. Результатыанонимного анкетирования больных рецидивирую-щим генитальным герпесом. Актуальные проблемыдерматологии и венерологии 2000;2:126.
  • 9. Анохин В.А. Современные принципы клинико-лабо-раторной диагностики герпетических инфекций. Ка-зан мед журн 1999;2:127-9.
  • 10. Климова Р.Р., Масалова О.В., Атанадзе С.Н., Кущ А.А.Моноклональные антитела в диагностике инфекций,вызываемых вирусом простого герпеса. Журн микро-биол 1999;5:99-103.
  • 11. Spruance S.L., Tyring S.K., DeGregorio B., et al. A large-scale, placebo-controlled, dose-ranging trial of peroralvalaciclovir for episodic treatment of recurrent herpesgenitalis. Arch Intern Med 1996;156:1729-35.
  • 12. Earnshaw D.L., Bacon T.H., Darlison S.J., et al. Mode ofantiviral action of penciclovir in MRC-5 cells infectedwithherpes simplex virustype-1 (HSV-I) HSV-2 andvaricellaZoster virus. Antimicrob Agents Chemother1992;36:2747-57.
  • 13. Fife K.H., Barabarash R.A., Rudolph T., et al.Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an internatio-nal, multicenter, double-blind, randomized clinical trial.Sex Transm Dis 1997;24:481-6.
  • 14. Кудашов Н.И., Озерова О.Е., Ворошилова Г.П. О ро-ли вируса герпеса в патогенезе церебральных повреж-дений и висцеральных нарушений и новорожденных.Акуш и гин 1990;1:24.
  • 15. Хаитов Р.М, Пинегин Б.В. Современные представле-ния о защите организма от инфекции. Иммунология2000;1:61-4.
  • 16. Климова Р.Р., Масалова О.В., Семенова Т.Б., Гребен-ча С.В., Абрамова Н.Б., Кущ А.А. Детекция антигенавируса простого герпеса 1-го и 2-го типов при помощимоноклональных антител в клинических образцах.Журн микробиол 1999;6:76-80.
  • 17. Men G.J., Benedetti J., Ashley R., et al. Risk factors forthe sexual transmission of genital herpes. Ann InternMed 1992;116:197-202.
  • 18. Яцуха М.В., Бобкова И.Н., Рыбакова Е.Ю., Новико-ва А.Г. Динамика заболеваемости вирусными аноге-нитальными инфекциями в 1993–1998 годах. Акту-альные проблемы дерматологии и венерологии2000;2:124.
  • 19. Кунгуров Н.В., Герасимова Н.М., Кузовкова Т.В.Сравнительная характеристика фамцикловира, вала-цикловира и ацикловира в терапии рецидивирующегогенитального герпеса. Актуальные проблемы дерма-тологии и венерологии: Сб. науч. работ. Москва; 2000.с. 35.
  • 20. Wald A., Zeh J., Barnum G., et al. Suppression of sub-clinical shedding ofherpes simplex virustype 2 withacyclovir. Ann Intern Med 1996;124:8-15.
  • 21. Mertz G.J., Schmidt D., Jourden J.L., et al. Frequency ofacquisition of first-episode genital infection withherpessimplex virusfrom symptomatic and asymptomatic sourcecontacts. Sex Transm Dis 1985;12:33-9.
  • 22. Wald A., Warren T., Hu H., et al. Suppression of subclin-ical shedding ofherpes simplex virustype 2 in the genitaltract with valaciclovir [abstract no. H-82]. The 38thInterscience Conference on Antimicrobial Agents andChemotherapy: 1998 Sep 24–27; San Diego (CA).
  • 23. Кубанова А.А., Масюкова С.А., Федоров С.М., Резай-кина А.В., Владимирова Е.В. Клинико-лабораторнаяоценка эффективности фамцикловира при рецидиви-рующем генитальном герпесе. Материалы научно-практической конференции, посвященной 75-летиюЦКВИ. Москва; 1996. с. 55-6.
  • 24. Масюкова С.А., Владимирова Е.В., Покровская С.Б.Противовирусная терапия при генитальном герпесе.РМЖ 2000;15:654-5.
  • 25. Хахалин Л.Н., Соловьева Е.В. Герпесвирусные забо-левания человека. Клин фарм тер 1998;1:72-6.
  • 26. Гусейнова З.К., Алиева П.М., Егорова Н.Б. ВакцинаВП-4 в лечении больных герпесом. Актуальные во-просы дерматологии и венерологии: Сб. науч. работ.Москва; 1998. с. 155-7.
  • 27. Тихонова Л.И. О состоянии заболеваемости болезня-ми, передаваемыми половым путем, и мерах по ихпредупреждению в России. ЗППП 1997;4:22-6.
  • 28. Шахгильдян В.И. Цитомегаловирусная инфекция.Новый мед журн 1997;2:2-6.
  • 29. Исаков В.А., Архипов Г.С., Аспель Ю.В., Исаков Д.В.,Ермоленко Д.К., Коваленко А. Л. и др. Иммунопатоге-нез и лечение генитального герпеса и хламидиоза. Ру-ководство для врачей. СПб; 1997.
  • 30. Аковбян В.А., Борисенко К.К. Современная терапияболезней, передаваемых половым путем. МатериалыVII Российского съезда дерматологов и венерологов.Казань; 1995. с. 126.
  • 31. Кицак В.Я. Успехи молекулярной биологии герпесви-русов и перспективы решения прикладных задач диа-гностики, терапии, эпидемиологии и профилактикигерпесвирусных инфекций. Актуальные вопросы эпи-демиологии инфекционных болезней 1997;2:294-8.
  • 32. Дубенский В.В. Гематологические и иммунологиче-ские показатели при остром и хроническом гениталь-ном герпесе. Актуальные проблемы дерматологии ивенерологии 2000;2:44.
  • 33. Владимирова Е.В. Эффективность фамцикловира влечении рецидивирующего гениального герпеса [дис-сертация канд]. 1998.
  • 34. Elion G.B., Furman P.A., Fyfe J.A., et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxy-ethoxymethyl)guanine. Proc Nat Acad Sci USA1977;74:5716-20.
  • 35. Patel R., Bodsvvorth N.J., Woolley I., et al. Valaciclovirfor the suppression of recurrent genital HSV infection: aplacebo-controlled study of once-daily therapy.Genitourin Med 1997;73:105-9.
  • 36. Vere Hodge R.A. Famciclovir and penciclovir: the modeof action of Famciclovir including its conversion to pen-ciclovir. Antiviral Chemother 1993;4:64-7.
  • 37. Centers for Disease Control and Prevention. Sexuallytransmitted diseases treatment guidelines 2002. MMWR2002;51 (No. RR-6).
  • 38. Patel R., Barton S.E., Brown D., Cowan F.M., King-horn G.R., Munday P.E., et al. European guidelines forthe management of genital herpes. Int J STD/AIDS2001;12(Suppl. 3):34-9.
  • 39. Bryson Y.J., Dillon M., Lovett M., et al. Treatment offirst episodes of genitalherpes simplex virusinfection withoral acyclovir: a randomized double-blind controlled trialin normal subjects. N Engl J Med 1983;308:916-21.
  • 40. Corey L., Fife K., Benedetii J.K., et al. Intravenous acy-clovir for the treatment of primary genital herpes. AnnIntern Med 1983;98:914-21
  • 41. Wald A., Benedetti J., Davis G., et al. A randomized, dou-ble-blind, comparative trial comparing high- and stan-dard-dose oral acyclovir for first-episode genital herpesinfections. Antimicrob Agents Chemother 1994;38:174-6.
  • 42. Murphy S.M., Ruck F., Kitchin V.S., et al. Oral famciclo-vir (FCV) a new antiherpes agent: comparative studywith acyclovir in clinic initiated treatment of firstepisode genital herpes (FGH) [abstract]. The 2ndCongress of the European Academy of Dermatology andVenereology (EADV) 1991; Athens.
  • 43. Tyring S.K., Douglas J.M., Corey L., et al. A randomized,placebo-controlled comparison of oral valaciclovir andacyclovir in immunocompetent patients with recurrentgenital herpes infections. Arch Dermatol 1998;134:185-91.
  • 44. Bodsvorlh N.J., Crooks R.J., Berell S., et al. Valaciclovirversus acyclovir in patient initiated treatment of recur-rent genital herpes: a randomized, double-blind trial.Genitourin Med 1997;73:110-60.
  • 45. Sacks S.L., Aoki F.Y., Diaz-Mitoma F., et al. Patient-ini-tiated, twice daily oral famciclovir for early recurrentgenital herpes: a randomized double-blind multicenterinvestigation. JAMA 1996:276:44-9.
  • 46. Mertz G.J., Eron L., Goldberg L., et al. Prolonged contin-uous versus intermittent oral acyclovir treatment in nor-mal adults with frequently recurring genitalherpes simplex virusinfection. Am J Med 1988;85:14-9.
  • 47. Perrin L., Hirscel B. Combinalion therapy in primaryHIV infection. Antiviral Res 1996;29:87-9.
  • 48. Carney O., Ross E., Ikkos G., et al. The effect of suppres-sive acyclovir on the psychological morbidity associatedwith recurrent genital herpes. Genitourin Med1993;69:457-9.
  • 49. Reitano M., Tyring S., Lang W., et al. Valaciclovir for thesuppression of recurrent genitalherpes simplex virusinfection: a large-scale dose range-finding study. J InfectDis 1998;178:603-10.
  • 50. Mertz G.J., Loveless M.O., Levin M.J., et al. Oral famci-clovir for the suppression of recurrent genitalherpes simplex virusinfection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med1997;157:343-9.
  • 51. Diaz-Mitoma F., Sibbald R.G., Sharon S.D., et al. Oralfamciclovir for the suppression of recurrent genital her-pes: a randomized controlled trial. JAMA 1998;280:887-92.
  • 52. Sacks S.L., Hughes A., Rennie B., et al. Famciclovir forsuppression of asymptomatic and symptomatic recurrentgenital herpes shedding: a randomized, double-blind,double dummy, parallel group, placebo-controlled trial(abstract no. H-73]. The 37th Interscience Conferenceon Antimicrobial Agents and Chemotherapy: 1997; Sep28–Oct 1; Toronto.
  • 53. Sacks S.L., Shafran S.D. BID Famciclovir suppression ofasymptomatic genitalherpes simplex virusshedding inmen [abstract no. H-12|. Abstracts of the 38thInterscience Conference on Antimicrobial Agents andChemotherapy: 1998 Sep 24–27; San Diego (CA).
  • 54. Schacker Т., Нu Н., Koelle DM., el al. Famciclovir for thesuppression of symptomatic and asymptomaticherpessimplex virusreactivation in HIV-infected persons. AnnIntern Med 1998;128:21-8.
  • 55. Corey L., Tyring S., Beutner K., et al. Once daily val-aciclovir reduces transmission of genital herpes.Proceedings of the 42nd ICAAC. Sep 27–30, 2002. San-Diego, USA. Abstract LB-3.
  • 56. Brown Z.A., Selke S., Zeh J., et al. The acquisition of herpes simplex virusduring pregnancy. N Engl J Med1997;337:509-15.
  • 57. Parris D., Harrington J.E.Herpes simplex virusvariantsresistant to high concentrations of acyclovir exist in cli-nical isolates. Antimicrob Agents Chemother 1982;22:71-7.
  • 58. Nugier F., Colin J.N., Aymard M., et al. Occurrence andcharacterization of acyclovir-resistantherpes simplexvirusisolates: report on a two-year sensitivity screeningsurvey. J Med Virol 1992;36:1-12.
  • 59. Kost R.O., Hill E.L., Tigges M., et al. Brief report: recur-rent acyclovir-resistant genital herpes in an immunocom-petent patient. N Engl J Med 1993;329:1777-82.
  • 60. Blower S.M., Porco T.C., Darby G. Predicting and pre-venting the emergence of antiviral drug resistance inHSV-2. Nat Med 1998;4:673-8.
  • 61. Wagstaff A.J., Bryson H.M. Foscarnet: a reappraisal of itsantiviral activity, pharmacokinetic properties and thera-peutic use in immunocompromised patients with viralinfections. Drugs 1994;48:199-226.
  • 62. Barton S., Munday R., Kinghorn G., et al. Topical treat-ment of recurrent genitalherpes simplex virusinfectionswith trisodium phosphonoformate (foscarnet): doubleblind, placebo controlled, multicentre study. GenitourinMed 1986:62:247-50.
  • 63. Swetter S.M., Hill E.L., Kern E.R., et al. Chronic vulvarulceration in an immunocompetent woman due toacyclovir-resistant, thymidine kinase-deficientherpessimplex virus. J Infect Dis 1998;177:543-50.
  • 64. Sacks S.L., Reece D.E., Galloway P., et al. Acyclovir(ACV) resistance inherpes simplex virus(HSV) isolatesfrom a patient with esophagitis: a thymidine kinase (TK)positive, foscarnet (PFA) resistant strain with responseto intravenous PFA. 27th Interscience Conference onAntimicrobial Agents and Chemotherapy: 1987 Oct 4–7;New York (NY).
  • 65. Jones R.J., Bischofberger N.J. Minireview: nucleotideprodrugs. Antiviral Res 1995;27:1-17.
  • 66. Mendel D.B., Barkhimer D.B., Chen M.S. Biochemicalbasis for increased susceptibility to cidofovir ofherpessimplex viruses with altered or deficient thymidinekinaseactivity. Antimicrob Agents Chemother 1995;39:2120-2.
  • 67. Naesens L., Snoeck R., Andrei G., et al. HPMPC (cido-fovir). PMEA (adefovir) and related acyclic nucleosidephosphonate analogues: a review of their pharmacologyand clinical potential in the treatment of viral infections.Antiviral Chem Chemother 1997;8:1-23.
  • 68. Palmer J., Vogt P.E., Kern E.R. Prevention and treat-ment of experimental genitalherpes simplex virustype 2(HSV-2) infections with topical HPMPC [abstractno. 205]. Antiviral Res 1995;26:A334.
  • 69. Lalezari J., Schacker T., Feinberg J., et al. A randomized,double-blind, placebo-controlled trial of cidofovir gel forthe treatment of acyclovir-unresponsive mucocutaneousherpes simplex virusinfection in patients with AIDS. JInfect Dis 1997;176:892-8.
  • 70. Murphy M., Morley A., Eglin R.P., et al. Topical trifluri-dine for mucocutaneous acyclovir-resistant herpes sim-plex II in AIDS patient [letter]. Lancet 1992;340:1040.
  • 71. Sacks S.L., Varner T.L., Davics K.S., el al. Randomizeddouble-blind, placebo-controlled, patient-initiated studyof topical high- and low-dose interferon with nonoxynol-9in the treatment of recurrent genital herpes. J Infect Dis1990;12:692-8.
  • 72. Lebwohl M., Sacks S., Conan M., et al. Recombinantalpha-2 interferon gel in treatment of recurrent herpesgenitalis. Antiviral Res 1992;17:235-43.
  • 73. Koyano S., Suzulani T., Yoshida I., et al. Analysis of phos-phorylation pathways of antiherpesvirus nucleosides byvaricella-zoster virus-specific enzymes. AntimicrobAgents Chemother 1996;40:920-3.
  • 74. Tenney D.J., Yamanaka G., Voss S.M., et al. Lobucavir isphosphorylated in human cytomegalovirus-infected anduninfected cells and inhibits the viral DNA polymerase.Antimicrob Agents Chemother 1997;41:2680-5.
  • 75. Petty B.G., Saito H., Summerill R.S., et al. Pharmaco-kinetics and bioavailabilily of cygalovir (BMS-180194)in asymptomatic HIV- and CMV-seropositive volunteers[abstract]. Antiviral Res 1994; 23 (Suppl 1):18.
  • 76. Sacks S.L., Tyrrell L.D., Lawee D., et al. Randomized,double-blind, placebo-controlled, clinic-initiated,Canadian multicenter trial of topical edoxudine 3,0%cream in the treatment of recurrent genital herpes. JInfect Dis 1991;164:665-72.
  • 77. Flamel Technologies. Viropump investigator’s brochure.Venissieux: Flamel Technologies, 1998.
  • 78. Sauder D., Tomai M., McDermott D., et al. Systemic andcutaneous pharmacodynamics of topical R-848 gel inhumans [abstract]. The 38th Interscience Conference onAntimicrobial Agents and Chemotherapy: 1998 Sep24–27; San Diego (CA): A-90.
  • 79. Spruance S.L., Tyring S., Bleazard C., et al. Immuno-modulation to decrease recurrences of herpes genitalis: adouble-blind, dose ranging study of topical R-848[abstract]. The 40th Interscience Conference on Anti-microbial Agents and Chemotherapy: 2000 Sep 17–20:Toronto: A466.
  • 80. Kuklin N.A., Daheshia M., Cluin S., et al. Role of mucosal immunity inherpes simplex virusinfection. J Immunol1998;160:5998-6003.
  • 81. Mert G.J., Hasley R., Burke R.L., et al. Double-blind, placebo-controlled trial of aherpes simplex virustype 2glycoprotein vaccine in persons at high risk for genitalherpes infection. J Infect Dis 1990;161:653-60.
  • 82. Corey L., Langenberg A.C., Ashley R., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2infection: two randomized controlled trials. Chiron HSVVaccine Study Group. JAMA 1999;282:331-40.
  • 83. Straus S.E., Corcy L., Burke R.L., et al. Placebo-controlled trial of vaccination with recombinant glycopro-tein D ofherpes simplex virustype 2 for immunotherapyof genital herpes. Lancet 1994;343:1460-5.
  • 84. Straus S.E., Wald A., Kost R.G., et al. Immunotherapy of recurrent genital herpes with recombinantherpes simplexvirustype 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176:1129-34.
  • 85. Mastrolorenzo A., Tuadrith L., Salunbeni L., et al.Multicentre clinical trial withherpes simplex virusvac-cine in recurrent herpes infection. Int J STD/AIDS1995;6:431-5.
  • 86. Spruance S. Gender-specific efficacy of a prophylacticSBAS4-adjuvanted gD2 subunit vaccine against genitalherpes disease (GHD): results of two clinical efficacy tri-als [abstract]. The 40th Interscience Conference onAntimicrobial Agents and Chemotherapy: 2000 Sep17–20; Toronto: L-6.
  • 87. Bourne N., Stanberry L.R., Bernstein D.I., et al. DNAimmunization against experimental genitalherpes simplex virusinfection. J Infect Dis 1996;173:800-7.
  • 88. Hickling J.K., Chisholm S.E., Duncan I.A., et al. Im-munogenity of a disabled infectious single cycle HSV-2vaccine in phase I clinical trials in HSV-2 seropositiveand seronegalive volunteers [abstract no. 22.008].Abstracts of the X International Congress on InfectiousDiseases: 1998, Boston.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared